Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy

Expert Opinion on Biological Therapy

Volumn 8, Issue 7, 2008, Pages 993-1001

  Morishita, Mariko ^b   Leonard, Robert C ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Filgrastim; G CSF; Neutropenia; Pegfilgrastim

Indexed keywords

ALKYLATING AGENT; ANALGESIC AGENT; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE RESPIRATORY TRACT DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ASTHENIA; B CELL LYMPHOMA; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; DYSPEPSIA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HEADACHE; HEALTH CARE; HEALTH CARE COST; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INSOMNIA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIPHERAL EDEMA; QUALITY OF LIFE; REFRACTORY PERIOD; REVIEW; SICKLE CELL CRISIS; SIDE EFFECT; SPLEEN RUPTURE; STOMATITIS; TASTE DISORDER; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; PLACEBOS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47549107114     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.7.993     Document Type: Review

References (75)

1. Stewart BW, Kleihaus P, editors, World Cancer Report. Lyon, France: IARC Press; 2003
2. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
3. Gabrilove JL, Jakubowski A, Scher H, et al. The effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22
4. Morstyn G, Campbell L, Souza LM, et al. Effects of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-72
5. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
6. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24
7. Blackwell S, Crawford J. Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: Morstyn G, Dexter TM, Foote MA, editors, Filgrastim (r-metHuG-CSF) in clinical practice. New York, NY: Marcel Dekker, Inc. 1993:103-16
8. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990;66:1124-9
9. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77
10. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993;4:651-6
11. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6
12. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005;330:217-22
13. Leonard RC, Miles D, Thomas R, et al. UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-8
14. Ozer H, Armitage JO, Bennert CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85
15. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508
16. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony- stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60
17. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109-18
18. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995;13:1328-35
19. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996;347:353-7
20. Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose chemotherapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor mobilized peripheral blood stem cells. J Clin Oncol 1994;12:2176-86
21. Schmitz N, Dreger P, Zander AR, et al. Results of a randomized controlled multicenter study of recombinant human granulocyte colony stimulating factor (filgrastim) in patients with Hodgkins disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261-6
22. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404
23. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant trearmenr of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9
24. Aapro MS, Cameron DA, Pettengell R, et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
25. Crawford J, Althaus B, Armitage J, et al. National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:188-202
26. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
27. Welte K, Gabrilove J, Bronchud, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88(6):1907-29
28. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-34
29. Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989;74:1303-7
30. Roskos LK, Yang B, Schwab G, et al. A cytokinetic model of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the "self- regulation" of SD/01 elimination in non-small cell lung cancer (NSCLC) parients [abstract]. Blood 1998;92(Suppl 1):507a
31. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304
32. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8
33. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-44
34. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 2002;62(Suppl 1):79-88
35. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007;27:1387-93
36. Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006;46:747-57
37. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled Phase III study. J Clin Oncol 2005;23(6):1178-84
38. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter Phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
39. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9
40. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95
41. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrasrim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
42. Arshad M, Seiter K, Bilaniuk J, et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005;23:8533-4
43. Kuendgen A, Fenk R, Bruns I, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;38:69-70
44. Hatzimichael E, Benetatos L, Stebbing J, et al. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006;28:416-8
45. Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007;25:247-8
46. Eisenbeis CF, Winn D, Poelman S, et al. A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol 2001;80:121-3
47. Arimura K, Inoue H, Kukita T, et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005;90(ECR10):e27-29
48. Adler BK, Salzman DE, Carabasi MH, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:3313-4
49. Adkins DR. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor. J Clin Oncol 1998;16:812-3
50. White JM, Mufti GJ, Salisbury JR, et al. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol 2006;31:206-7
51. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-9
52. Engen A, Bredenfeld H, Döhner H, et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a Phase II study. Haematologica 2006;91:546-9
53. Pirker R, Ulsperger E, Messner J, et al. Achieving full-dose, on-schedule adminisrrarion of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 2006;184:279-85
54. Nabholtz JM, Falkson C, Campos D, et al., TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as firsr-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J Clin Oncol 2003;21:968-75
55. Alba E, Martin M, Ramos M, et al., Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxotubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III study. J Clin Oncol 2004;22:2587-93
56. George S, Yunus F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-6
57. Grigg A, Solal-Celigny P, Hoskin P, et al., International Study Group. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1503-8
58. Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340-7
59. Piedbois P, Serin D, Priou F, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epitubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized Phase II study. Ann Oncol 2007;18:52-7
60. Kahan Z, Spanik S, Wagnerova M, et al. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 2008: published online, January 14 2008, doi:10.1007/s10549-008-9894-7
61. Mey UJ, Maier A, Schmidt-Wolf IG, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007;15:877-84
62. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a Phase II study of feasibility and toxicity. Haematological 2006;91:496-502
63. Mey UJ, Maier A, Kleinschmidt R, et al. Pharmacokinetics and efficacy of pegfilgrastim as hematopoietic support for dose-dense every-2-week chemo-immunotherapy with R-CHOP as first-line therapy in elderly patients with diffuse large B cell lymphoma [abstract 17531]. ASCO Annual Meeting Proceedings Part I; J Clin Oncol 2006;24(18S Suppl)
64. Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007;12:484-94
65. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients. Oncologist 2001;6:441-5
66. Bennett CL, Armitage JL, LeSage S, et al. Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells 1994;12:424-9
67. Bennett CL, Weeks JA, Somerfield MR, et al. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 1999;17:3676-81
68. Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol 2000;18:1764-70
69. Bach PB: Using practice guidelines to assess cancer care quality. J Clin Oncol 2005;23:9041-3
70. Harlan L, Greene AL, Limin X, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005;23:9079-88
71. McNeil C. NCCN guidelines advocate wider use of colony-stimulating factor. J Natl Cancer Inst 2005;97:710-1
72. Timmer-Bonte JN, De Boo TM, Smit HJ, et al. Prevention of hemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized Phase III study. J Clin Oncol 2005;23:7974-84
73. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer parients. Cancer 2006;106:2258-66
74. Courtney DM, Aldeen AZ, Gorman SM, et al. Cancer-associated neutropenic fever: clinical ourcome and economic costs of emergency department care. Oncologist 2007;12:1019-26
75. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer parients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67